These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28421682)

  • 1. Predicting abstinence from methamphetamine use after residential rehabilitation: Findings from the Methamphetamine Treatment Evaluation Study.
    McKetin R; Kothe A; Baker AL; Lee NK; Ross J; Lubman DI
    Drug Alcohol Rev; 2018 Jan; 37(1):70-78. PubMed ID: 28421682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES).
    McKetin R; Najman JM; Baker AL; Lubman DI; Dawe S; Ali R; Lee NK; Mattick RP; Mamun A
    Addiction; 2012 Nov; 107(11):1998-2008. PubMed ID: 22564065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health service utilisation attributable to methamphetamine use in Australia: Patterns, predictors and national impact.
    McKetin R; Degenhardt L; Shanahan M; Baker AL; Lee NK; Lubman DI
    Drug Alcohol Rev; 2018 Feb; 37(2):196-204. PubMed ID: 28294443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Exercise On Depression and Anxiety Symptoms Among Abstinent Methamphetamine-Dependent Individuals in A Residential Treatment Setting.
    Rawson RA; Chudzynski J; Gonzales R; Mooney L; Dickerson D; Ang A; Dolezal B; Cooper CB
    J Subst Abuse Treat; 2015 Oct; 57():36-40. PubMed ID: 25934458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Course of Psychiatric Symptoms and Abstinence among Methamphetamine-Dependent Persons in Sober Living Recovery Homes.
    Polcin DL; Witbrodt J; Korcha R; Gupta S; Mericle AA
    J Psychoactive Drugs; 2016; 48(3):173-80. PubMed ID: 27184803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of detection of methamphetamine in hair after abstinence.
    Suwannachom N; Thananchai T; Junkuy A; O'Brien TE; Sribanditmongkol P
    Forensic Sci Int; 2015 Sep; 254():80-6. PubMed ID: 26197350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and acceptability of approach bias modification during methamphetamine withdrawal and related methamphetamine use outcomes.
    Manning V; Garfield JBB; Mroz K; Campbell SC; Piercy H; Staiger PK; Lum JAG; Lubman DI; Verdejo-Garcia A
    J Subst Abuse Treat; 2019 Nov; 106():12-18. PubMed ID: 31540606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of drug dependence in a Queensland (Australia) sample of Indigenous and non-Indigenous people who inject drugs.
    Smirnov A; Kemp R; Ward J; Henderson S; Williams S; Dev A; Najman JM
    Drug Alcohol Rev; 2016 Sep; 35(5):611-9. PubMed ID: 27241554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study.
    Rafizadeh R; Frankow L; Mahmood H; Poonia S; Mathew N; Danilewitz M; Bousman CA; Honer WG; Schütz CG
    J Psychopharmacol; 2023 Oct; 37(10):1040-1048. PubMed ID: 37539972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of methamphetamine abuse treatment: Predictors of treatment completion and comparison of two residential treatment programs.
    Kamp F; Proebstl L; Hager L; Schreiber A; Riebschläger M; Neumann S; Straif M; Schacht-Jablonowsky M; Manz K; Soyka M; Koller G
    Drug Alcohol Depend; 2019 Aug; 201():8-15. PubMed ID: 31154239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
    Shearer J; Darke S; Rodgers C; Slade T; van Beek I; Lewis J; Brady D; McKetin R; Mattick RP; Wodak A
    Addiction; 2009 Feb; 104(2):224-33. PubMed ID: 19149817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study.
    Nordahl TE; Salo R; Natsuaki Y; Galloway GP; Waters C; Moore CD; Kile S; Buonocore MH
    Arch Gen Psychiatry; 2005 Apr; 62(4):444-52. PubMed ID: 15809412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors.
    Brecht ML; Herbeck D
    Drug Alcohol Depend; 2014 Jun; 139():18-25. PubMed ID: 24685563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study.
    McKetin R; Lubman DI; Baker AL; Dawe S; Ali RL
    JAMA Psychiatry; 2013 Mar; 70(3):319-24. PubMed ID: 23303471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential benefits of quetiapine in the treatment of substance dependence disorders.
    Sattar SP; Bhatia SC; Petty F
    J Psychiatry Neurosci; 2004 Nov; 29(6):452-7. PubMed ID: 15644986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 12- and 18-month follow-up after residential treatment of methamphetamine dependence: Influence of treatment drop-out and different treatment concepts.
    Kamp F; Hager L; Proebstl L; Schreiber A; Riebschläger M; Neumann S; Straif M; Schacht-Jablonowsky M; Falkai P; Pogarell O; Manz K; Soyka M; Koller G
    J Psychiatr Res; 2020 Oct; 129():103-110. PubMed ID: 32652338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence.
    Cook R; Quinn B; Heinzerling K; Shoptaw S
    Addiction; 2017 Jun; 112(6):1077-1085. PubMed ID: 28107598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of relapse on cognition in abstinent methamphetamine abusers.
    Simon SL; Dacey J; Glynn S; Rawson R; Ling W
    J Subst Abuse Treat; 2004 Jul; 27(1):59-66. PubMed ID: 15223095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of the Serigaya Methamphetamine Relapse Prevention Program (SMARPP): for patients with drug use disorder: A study on factors influencing 1-year follow-up outcomes].
    Tanibuchi Y; Matsumoto T; Imamura F; Wakabayashi A; Kawachi H; Hikitsuchi E; Takano A; Yonezawa M; Kato T; Yamada M; Wachi A; Aboshi M; Wada K
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2016 Feb; 51(1):38-54. PubMed ID: 27295823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study.
    McKetin R; Lubman DI; Najman JM; Dawe S; Butterworth P; Baker AL
    Addiction; 2014 May; 109(5):798-806. PubMed ID: 24400972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.